Skip to main content
Premium Trial:

Request an Annual Quote

OncoTyrol to Conduct Validation Studies on Protagen UniArray Technology

NEW YORK (GenomeWeb News) – Protagen said today that it has formed a collaboration with OncoTyrol to conduct validation studies on the firm's UniArray technology platform.

The study aims to determine the "most robust combination of putative prostate cancer markers and optimizing the diagnostic protein biochip to proceed to clinical trials," Protagen CEO Stefan Müllner said in a statement.

Protagen said that it recently identified autoantigen candidates in the serum of patients with prostate cancer using its UniArray technology platform. The Dortmund, Germany-based firm hopes to develop a test targeting the intermediate patient risk group, which includes individuals with a PSA range of between 2.5 ng/ml and 4.0 ng/ml.

OncoTyrol is the K1 project for Personalized Cancer Medicine and includes a consortium of researchers at the Biomedical Campus Innsbruck as well as researchers from national and international academic and industrial partners.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.